## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.02 indicates fundamental undervaluation. Quality metrics strong (ROE 82%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($317.65)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Is There Still Value in Amgen After Its Strong 2025 Share Price Run?**
- Source: Simply Wall Street | 20251223T100742 | Somewhat-Bullish | Relevance: 100%
- Amgen's stock has performed well in 2025, but a Discounted Cash Flow (DCF) analysis suggests it is undervalued by 40.3%. The company's PE ratio of 25.5x is below Simply Wall St's Fair Ratio of 29.4x, indicating it may also be modestly undervalued on an earnings multiple basis. Different "Narratives" for Amgen's future, considering bull and bear cases, project Fair Values from $425 to $322.88.

**2. Is There Still Value in Amgen After Its Strong 2025 Share Price Run?**
- Source: Simply Wall Street | 20251223T094150 | Bullish | Relevance: 100%
- Amgen's stock has seen a significant run in 2025, but analysis suggests it may still be undervalued. A Discounted Cash Flow (DCF) model indicates a 40.3% discount to fair value, and its PE ratio also suggests it's modestly undervalued compared to its "Fair Ratio." The article further explores different valuation narratives for Amgen, ranging from a bullish case with a Fair Value of $425.00 to a bear case of $322.88.

**3. Amgen Stock After Hours (AMGN) on Dec. 22, 2025: FDA Clears New Prolia/Xgeva Biosimilars, Fitch Upgrades Credit — What to Know Before the Dec. 23 Open**
- Source: ts2.tech | 20251223T010708 | Neutral | Relevance: 100%
- Amgen (NASDAQ: AMGN) faces opposing forces before the December 23rd market open: the FDA approved new biosimilars for its blockbuster drugs, Prolia and XGEVA, which could increase competitive pressure. However, Fitch upgraded Amgen's credit rating to BBB+, signaling improved financial flexibility and a positive counterweight to biosimilar concerns. Investors will weigh these factors along with ongoing drug-pricing policy discussions and the impact of holiday-week liquidity.

**4. Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025**
- Source: ts2.tech | 20251222T180808 | Somewhat-Bullish | Relevance: 100%
- Amgen Inc. (NASDAQ: AMGN) is currently under investor scrutiny due to new White House drug-pricing agreements, notably a "most-favored-nation" (MFN) push, and potential impacts on 2026 earnings. Analysts suggest these deals might be more about political and tariff uncertainty reduction than immediate profit compression. The stock traded higher despite these developments, driven by strong Q3 2025 earnings and promising pipeline developments in obesity and oncology, though MFN policies and pipeline risks remain key considerations for investors.

**5. Assessing Amgen (AMGN) Valuation After UPLIZNA Approval and New U.S. Drug Pricing Agreements**
- Source: Simply Wall Street | 20251222T070842 | Neutral | Relevance: 100%
- Amgen (AMGN) has seen its valuation impacted by two significant events: the FDA approval of UPLIZNA for generalized myasthenia gravis and new U.S. drug pricing agreements. Despite a strong stock performance year-to-date and a significant five-year total shareholder return, analysts consider AMGN's current price slightly overvalued based on future earnings, while its P/E ratio suggests potential undervaluation compared to peers. The article discusses risks like drug pricing pressure and biosimilar competition, and encourages investors to conduct their own detailed analysis.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $304 | $329 | -8% |
| 2025-12-10 | Wells Fargo | $325 | $300 | +8% |
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-03 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.02 suggests fair value with growth premium. Forward P/E 15.1x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $178.5B |
| Beta | 0.45 |
| 52W Range | $257.05 - $346.38 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.02 |
| Forward P/E | 15.1 |
| Current P/E | 15.6 |
| YoY Growth | 3.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.8% over 5 days). Below STRENGTH zone by 4.6pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56. Elevated volume (1.9x 20MA), institutional activity likely. OFD pattern: +MUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.57% (CS: 48) | Neutral |
| RSI_14 | 55.6 | Neutral |
| MACD Histogram | -0.39 | Bearish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 1.036x | Above |
| vs SMA200 | 1.115x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $331.49
- **Stop Loss:** $317.65 (4.2% risk)
- **Target:** $359.17 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 86
- **Position Value:** $28,508.14
- **Portfolio %:** 28.51%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*